Salute e Benessere
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
CAM2056 is a monthly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist formulated with Camurus' proprietary FluidCrystal® technology.
Topline results from the Phase 1b study include:
FluidCrystal® is a registered trademark of Camurus. Wegovy® is a registered trademark of Novo Nordisk.
Fredrik Tiberg , President & CEO, CSO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the managing director, at 8:00 am CET on 10 November 2025 .
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/camurus-ab/r/camurus-reports-positive-topline-results-for-cam2056--semaglutide-monthly-depot,c4264164
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/camurus-reports-positive-topline-results-for-cam2056-semaglutide-monthly-depot-302609929.html